Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Pediatr Pulmonol ; 55(2): 360-368, 2020 02.
Article in English | MEDLINE | ID: covidwho-1064413


BACKGROUND: The use of medications to treat respiratory conditions of extreme prematurity is often based upon studies of adults or children over 2 years of age. Little is known about the spectrum of medications used or dosing ranges. To inform the design of future studies, we conducted a prospective analysis of respiratory medication exposure among 832 extremely low gestational age neonates. METHODS: The prematurity and respiratory outcomes program (PROP) enrolled neonates less than 29-week gestation from 6 centers incorporating 13 clinical sites. We collected recorded daily "respiratory" medications given along with dosing information through 40-week postmenstrual age or neonatal intensive care unit discharge if earlier. RESULTS: PROP participants were exposed to a wide range of respiratory medications, often at doses beyond published recommendations. Nearly 50% received caffeine and furosemide beyond published recommendations for cumulative dose. Those who developed bronchopulmonary dysplasia were more likely to receive treatment with respiratory medications. However, more than 30% of PROP subjects that did not develop bronchopulmonary dysplasia also were treated with diuretics, systemic steroids, and other respiratory medications. CONCLUSION: Extremely preterm neonates in PROP were exposed to high doses of medications at levels known to generate significant adverse effects. With limited evidence for efficacy, there is an urgent need for controlled trials in this vulnerable patient population.

Infant, Premature , Intensive Care Units, Neonatal , Bronchopulmonary Dysplasia/drug therapy , Child , Child, Preschool , Female , Gestational Age , Humans , Infant , Infant, Low Birth Weight , Infant, Newborn , Infant, Premature, Diseases/drug therapy , Male , Patient Discharge , Prospective Studies , Respiratory Tract Diseases/drug therapy , Steroids/therapeutic use
Pediatr Pulmonol ; 56(2): 539-550, 2021 02.
Article in English | MEDLINE | ID: covidwho-1023306


Coronavirus disease 2019 (COVID-19) has been an unprecedented and continuously evolving healthcare crisis. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spread rapidly and initially little was known about the virus or the clinical course for infected children. In the United States of America, the medical response has been regionalized, based on variation in community transmission of the virus and localized outbreaks. Pediatric pulmonary and sleep divisions evolved in response to administrative and clinical challenges. As the workforce transitioned to working remotely, video conferencing technology and multicenter collaborative efforts were implemented to create clinical protocols. The COVID-19 pandemic challenges the framework of current medical practice but also highlights the dynamic and cooperative nature of pediatric pulmonology and sleep medicine. Our response to this pandemic has laid the groundwork for future challenges.

COVID-19 , Lung Diseases/drug therapy , Sleep Wake Disorders/drug therapy , Child , Consensus , Humans , Pandemics , SARS-CoV-2
Pediatr Pulmonol ; 55(7): 1598-1600, 2020 07.
Article in English | MEDLINE | ID: covidwho-155146


The 2019 novel coronavirus (SARS-CoV-2) is endangering human health worldwide; scarcity of published pediatric cases and current literature and the absence of evidence-based guidelines necessitate international sharing of experience and personal communication. On 31 March 2020 the International Committee of the American Thoracic Society Pediatrics Assembly recorded an online podcast, during which pediatric pulmonologists worldwide shared their experience on the novel coronavirus disease (COVID-19) in children. The aim was to share personal experience in organizing pediatric care in different health care settings globally, protecting health care workers, and isolation practices. This manuscript summarizes the common themes of the podcast which centered around three main topics: more benign clinical disease and progression in pediatric cases compared to adults, a strong need for strategies to protect health care workers, and social or economic disparities as a barrier to successful pandemic control.

Coronavirus Infections/epidemiology , Pediatrics/trends , Pneumonia, Viral/epidemiology , Webcasts as Topic , Adult , Betacoronavirus , COVID-19 , Child , Chronic Disease , Communicable Disease Control/methods , Coronavirus Infections/complications , Disease Progression , Global Health , Healthcare Disparities , Hospitalization , Hospitals, Pediatric/organization & administration , Humans , Internationality , Occupational Health , Pandemics , Pediatrics/methods , Pneumonia, Viral/complications , Pulmonary Medicine , Quarantine , Respiration Disorders/complications , SARS-CoV-2 , United States